Q/C Technologies, Inc. (QCLS : NASDAQ)
Common Stock
$0.96
USD
+0.52 (118.45%)
Last updated: 2026-09-16
Get QCLS alerts:
QCLS
Q/C Technologies, Inc.
WealthAwesomePerformance
1 Day
+118.45%
1 Week
-45.84%
1 Month
-65.69%
YTD
-75.03%
Key Statistics
Market Cap
$7.90M
52W High
$8.94
52W Low
$0.42
P/E Ratio
-
50 Day MA
$2.69
200 Day MA
$3.76
Beta
2.11
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/16/2026 | $0.46 | $2.16 | $0.44 | $0.96 | $0.96 | 234,476,438 |
| 9/15/2026 | $0.46 | $0.50 | $0.42 | $0.44 | $0.44 | 3,923,835 |
| 9/14/2026 | $1.60 | $1.62 | $0.54 | $0.56 | $0.56 | 10,185,572 |
| 9/11/2026 | $1.67 | $1.76 | $1.65 | $1.71 | $1.71 | 241,935 |
| 9/10/2026 | $1.74 | $1.78 | $1.64 | $1.65 | $1.65 | 227,900 |
| 9/9/2026 | $1.90 | $1.91 | $1.78 | $1.78 | $1.78 | 190,300 |
| 9/8/2026 | $1.83 | $2.02 | $1.76 | $1.93 | $1.93 | 443,600 |
| 9/4/2026 | $1.89 | $1.92 | $1.77 | $1.79 | $1.79 | 360,600 |
| 9/3/2026 | $1.94 | $1.97 | $1.85 | $1.88 | $1.88 | 351,400 |
| 9/2/2026 | $2.10 | $2.10 | $1.88 | $1.91 | $1.91 | 563,600 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on QCLS's historical volatility
30-Day Vol
409.9%
Annualized
90-Day Vol
288.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$0.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.91 | US$0.22 – US$3.74 |
| 60 trading days | US$0.86 | US$0.12 – US$6.32 |
| 90 trading days | US$0.81 | US$0.07 – US$9.34 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -108.00%
- EPS (Diluted)
- -201.40
- Book Value
- 1.95
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About QCLS.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.19 | +41.54% |